Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling ...

[laughs] The reason I think that there was some interest in that is that the Gila Monster only eats 5-10 times ... to a pill form of a peptide to make it work and in fact, there is a Novo Nordisk ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

Conclave explores obesity as a metabolic disease, the role of medication like Ozempic, and holistic weight loss strategies, ...